Biologics and Novel Therapeutics Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Antibody-Drug Conjugates (ADCs) DMPK and Bioanalytical Services

Antibody-drug conjugates require a different bioanalytical framework from both conventional monoclonal antibodies and small-molecule targeted therapies. An ADC is a linked system composed of antibody carrier, linker, payload, conjugated species, released payload, and catabolism-driven products.

Creative Proteomics develops research-use ADC workflows that separate total antibody, conjugated antibody, intact ADC, free payload, payload-related species, DAR distribution, cathepsin-mediated release, plasma stability, and tumor-associated processing into interpretable bioanalytical readouts.

Browse ADC Drug Index Request Custom ADC Bioanalysis Support

Multi-Readout ADC BioanalysisSeparate total antibody, conjugated antibody, intact ADC, and free payload rather than relying on one generic concentration value.

Payload Release LogicEvaluate cathepsin-associated processing, linker-payload stability, and plasma-versus-tumor release behavior.

DAR and Species ControlTrack drug-to-antibody ratio and conjugated species changes that may alter ADC interpretation.

ADC Study Logic ANTIBODY → LINKER → PAYLOAD → DAR

🧲

Total vs Conjugated AntibodyDefine whether the workflow measures carrier antibody, payload-conjugated antibody, or intact ADC signal.

✂️

Cathepsin-Linked ReleaseAssess payload release in plasma and tumor-relevant matrices instead of inferring release from antibody exposure.

⚗️

Payload LayerQuantify free payload, payload-related species, and payload-specific metabolism where relevant.

📊

DAR DistributionMonitor drug-to-antibody ratio and conjugated species heterogeneity as independent ADC readouts.

ADC-specific bioanalysis.We connect antibody carrier exposure, payload release, free payload quantification, plasma/tumor sample analysis, DAR profiling, and linker-payload stability into one method plan.

ADC Drug Index

Map the ADC Readout Before Method Development

Route ADC research by molecular readout: total antibody, conjugated antibody, intact ADC, free payload, cathepsin-mediated release, plasma/tumor sample behavior, DAR analysis, or custom ADC multi-readout bioanalysis.

A-Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the index shows only ADC entries matching all selected values.

2 entries · Page 1 of 1

Analytical Pain Points

What Drives Assay Failure in ADC Studies?

ADC assays fail when they are treated as ordinary mAb assays. Total antibody may not describe payload release, DAR shift, deconjugation, free payload exposure, tumor-associated processing, or linker-payload stability.

Total antibody is not active ADC exposure

Total antibody can remain measurable after payload loss or DAR change. ADC interpretation needs carrier and conjugated readouts separated.

Total antibody measurement
Conjugated antibody bioanalysis
Intact ADC characterization

Payload release must be measured directly

Cathepsin-associated processing can affect released payload and tumor-relevant exposure. It should not be inferred from antibody concentration alone.

Cathepsin-mediated release
Free payload quantification
Plasma / tumor comparison

DAR can shift during disposition

Drug-to-antibody ratio may change through deconjugation, catabolism, or sample handling. One total ADC value can miss species heterogeneity.

DAR analysis
Conjugated species profiling
Intact / subunit workflows

Payload and antibody layers differ

The biologics carrier and small-molecule payload may require different extraction, quantification, and interpretation strategies.

Payload LC-MS/MS
Payload-related species review
Hybrid ADC workflow planning

Plasma stability and tumor release differ

Plasma stability evaluates circulating integrity, while tumor release evaluates local processing. The same assay may not answer both questions.

Plasma stability assessment
Tumor sample bioanalysis
Matrix-specific ADC methods

Focused Service Paths

Four Practical Routes for ADC Studies

Instead of treating ADCs as simple mAbs with attached payloads, choose the route according to the readout: carrier antibody, conjugated species, free payload, cathepsin release, DAR, or intact/subunit ADC profile.

Total and Conjugated Antibody Bioanalysis

For brentuximab vedotin, T-DM1 / trastuzumab emtansine, or related ADC exposure data in plasma, tumor, or other matrices.

Total antibody measurement
Conjugated antibody analysis
Intact ADC exposure
Plasma and tumor bioanalysis

Bioanalytical Quantification →

Payload and Free Payload Quantification

For projects where released payload, payload-related species, or payload exposure is central to ADC interpretation.

Free payload measurement
Payload-related species quantification
Payload exposure profiling
Payload-specific LC-MS/MS

LC-MS/MS Drug Quantification →

Cathepsin-Mediated Release and Stability

For studies where cathepsin processing, linker-payload stability, plasma stability, or tumor-associated release is the research objective.

Cathepsin-linked release
Plasma stability assessment
Tumor-associated release
Linker-payload review

Stability & Degradation Studies →

DAR and Intact / Subunit ADC Analysis

For projects requiring drug-to-antibody ratio, intact ADC profile, conjugated species distribution, or subunit-level characterization.

DAR analysis
Intact ADC characterization
Subunit ADC analysis
Conjugated species profiling

Intact Protein Mass Analysis →

Project Inquiry

Need Support for a Novel or Unlisted ADC?

If you are working with an antibody-drug conjugate, linker-payload analog, new ADC payload, cathepsin-released payload workflow, DAR analysis requirement, plasma stability question, tumor release study, or ADC multi-readout project, a single total antibody assay will not be enough.

Share your ADC, matrix, expected concentration range, antibody carrier, linker-payload chemistry, cathepsin release question, DAR analysis requirement, free payload objective, plasma stability concern, tumor sample type, and reporting needs.

Target ADC and matrix

Antibody carrier / payload

Cathepsin release question

DAR analysis needs

Free payload objective

Plasma / tumor sample type

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →